A Phase 1 interventional study of Tocilizumab in COVID-19, sponsored by Hoffmann-La Roche. Completed at 25 sites in 11 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2024-04-29.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.
Among the 38 studies testing tocilizumab in COVID-19, this one is the 36th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1, and was the 36th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Lebanese University · Sites in Lebanon
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 14 · Phase 4 2
First in 2016; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 150 across the 38 interventional studies. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing tocilizumab in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.
Drug: Tocilizumab
Participants will receive intravenous (IV) tocilizumab
Serum concentration of TCZ
Time frame: Through Day 28
Maximum serum concentration (Cmax) of TCZ
Time frame: Through Day 28
Area under the curve from Days 0-28 (AUC days 0-28) of TCZ
Time frame: Days 0-28
Serum concentration on Day 28 (C day 28) of TCZ
Time frame: Day 28
Clearance (CL) of TCZ
Time frame: Through Day 28
Volume of distribution of TCZ
Time frame: Through Day 28
Duration of 90% saturation of sIL-6R
Time frame: Through Day 28
Concentration of IL-6
Time frame: Through Day 60
Concentration of sIL-6R
Time frame: Through Day 60
Concentration of C-reactive protein (CRP)
Time frame: Through Day 60
Percentage of participants with adverse events
Time frame: Up to 60 days
Percentage of participants with severe adverse events
Time frame: Up to 60 days
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Mar 2024, 21 months.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 21 months is above that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab